The KEYNOTE-006 study, evaluating the efficacy of pembrolizumab in BRAF V600-mutant melanoma patients, reported a 5-year median OS of 32.7 months (95% CI 24.5–41.6) [69]. This evidence concerns the gene BRAF and melanoma.